

AZD-9668 Report

Authors:

Date: 1 April 2010

"Copyright 2010 CBDM.T SARL. All rights reserved. Any unauthorized use or disclosure is prohibited. The information herein was obtained from various sources; we do not guarantee its accuracy or completeness. This research report is prepared for general circulation and is circulated for general information only. It does not have regard to specific investment objectives, financial situation and the particular needs of any particular person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment and trading strategies discussed or recommended in this report and should understand that the statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Neither the information nor any opinion expressed constitutes an offer to buy or sell any securities or options or futures contracts. CBDM.T SARL accepts no responsibility or liability whatsoever for any expense, loss or damages arising out of or in any way connected with the use of all or any part of this report. CBDM.T SARL does not have long or short position in any securities or options of this issue(s)."



Table of Content

I.	Presentation – General Information	2
II.	Chronic Obstructive Pulmonary Disease	3
	Market Analysis	4
	Treatment Trends.....	5
	New Treatments for COPD	6
III.	Originator: AstraZeneca	8
IV.	Clinical Trials	9
	Clinical Trial List	9
V.	SWOT Analysis	11
VI.	News.....	12
	AZD 9668 AstraZeneca phase change II, Germany (COPD) AstraZeneca phase change II, UK, Canada (bronchiectasis).	12
	AZD 9668 AstraZeneca developing COPD treatment.	12
